Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 7.71 SEK -1.91%
Market Cap: 1.8B SEK
Have any thoughts about
Vicore Pharma Holding AB?
Write Note

Vicore Pharma Holding AB
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vicore Pharma Holding AB
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Vicore Pharma Holding AB
STO:VICO
Interest Income Expense
kr25.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Interest Income Expense
kr27.6m
CAGR 3-Years
N/A
CAGR 5-Years
31%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Interest Income Expense
kr2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Interest Income Expense
-kr82m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Interest Income Expense
-kr1.4B
CAGR 3-Years
-38%
CAGR 5-Years
-47%
CAGR 10-Years
-64%
BioArctic AB
STO:BIOA B
Interest Income Expense
kr12m
CAGR 3-Years
N/A
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

Vicore Pharma Holding AB
Glance View

Market Cap
1.8B SEK
Industry
Biotechnology

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

VICO Intrinsic Value
4.31 SEK
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Vicore Pharma Holding AB's Interest Income Expense?
Interest Income Expense
25.1m SEK

Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's Interest Income Expense amounts to 25.1m SEK.

What is Vicore Pharma Holding AB's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
613%

Over the last year, the Interest Income Expense growth was 613%.

Back to Top